Before Renewal Season: Five Questions Canadian Benefits Teams Should Be Asking About Regenerative Care

Benefits planning has a rhythm. Questions arrive in clusters, usually after an employee returns from leave with a story about a treatment nobody in the plan had heard of. Regenerative medicine is now producing those clusters with some regularity, and Canadian employers are discovering that their plan documents say very little about it.

The silence is not neutral. Where a plan is silent, decisions get made case by case — sometimes by an insurer, sometimes by a manager, occasionally by nobody. For a benefits team preparing for a 2026 renewal, the more efficient course is to ask the questions deliberately, in writing, while there is still time to amend language.

What follows is a set of five questions worth putting to your benefits advisor. They are not rhetorical. Each has an answer that ought to be documented before the next employee asks.

1. What does our plan actually say about out-of-country regenerative treatment?

Most group plans address out-of-country care through emergency travel provisions, which are designed for accidents and acute illness rather than elective procedures. Elective treatment abroad typically falls outside those provisions and is neither clearly included nor clearly excluded in the extended health language.

Ask for the specific clause. Ask whether experimental or investigational exclusions apply, and how the insurer determines which category a given therapy occupies. Then ask the harder question: if an employee asks whether their plan covers this, what is the approved answer they should be given? An employer that cannot answer that consistently is exposed to inconsistency complaints, and inconsistency is difficult to defend.

2. If an employee travels for treatment, who carries the liability?

This is the question benefits teams least want to ask, and the one that matters most. If an employer funds or facilitates treatment delivered in another jurisdiction, the boundaries of its responsibility need to be explicit — including whether the arrangement is a reimbursement benefit, an accommodation, or a discretionary exception.

Ask whether the insurer or the employer bears responsibility for verifying the credentials of a foreign clinic, and whether a referral made by an occupational health nurse or a manager creates an implied endorsement. Clarity here protects both the employee and the organisation. Vague goodwill is not a policy.

3. How will return-to-work be sequenced?

Regenerative treatment produces a recovery curve measured in months, with loading restrictions and progressive rehabilitation. It is not equivalent to a surgical recovery, and it does not fit neatly into a standard return-to-work template built around a single procedure date.

Ask your advisor and your disability carrier how a gradual return would be structured, what documentation would be required at each stage, and whether an absence for treatment abroad is administered as sick leave, short-term disability, or an unpaid leave under provincial employment standards. In several provinces the notice and reinstatement rules differ depending on that classification, and the distinction is easier to make in advance than retrospectively.

4. Are our paramedical limits quietly deciding this for us?

Every group plan carries annual maximums for physiotherapy, massage therapy and chiropractic care. Those limits were set when rehabilitation was assumed to be short and domestic. A post-procedural course of physiotherapy can consume an annual maximum in a matter of weeks, leaving the employee to fund the remainder privately.

Ask what the realistic total rehabilitation cost looks like for a musculoskeletal claim under the current caps, and whether a higher paramedical maximum would reduce the duration of disability leave. For many plan sponsors, the arithmetic is more favourable than the intuition suggests: the cost of added sessions is often smaller than the cost of extended absence.

5. What are we measuring, and are we asking the right employees?

Most employers have no data on how many staff have pursued treatment abroad, how much they paid, or what happened afterwards. Without that, renewal decisions are made on impression rather than evidence.

Ask whether the insurer can report on out-of-country claims, paramedical utilisation patterns and musculoskeletal disability durations as a category. Then ask a question of your own workforce: an anonymous pulse survey on unmet musculoskeletal needs will usually reveal more than a claims summary, because the employees most likely to consider travelling for care are often the ones who have not yet filed a claim at all.

The case for asking now

None of these questions requires an employer to take a position for or against regenerative medicine. They require only that the plan's existing position be identified and stated. That is a modest administrative task in September and a considerably harder one in the middle of a disputed claim in February.

Benefits advisors are fielding these queries from other clients already. Employers who arrive at the 2026 renewal with written answers — on coverage, liability, return-to-work sequencing, paramedical adequacy and measurement — will spend the next cycle managing a plan. Those who do not will spend it managing individual conversations, one employee at a time, without a policy to point to.